Načítá se...
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
BACKGROUND: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by...
Uloženo v:
| Vydáno v: | J Virus Erad |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Mediscript Ltd
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892670/ https://ncbi.nlm.nih.gov/pubmed/29682298 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|